Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory FLT3‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.